Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new?

Shilan Mozaffari,Shekoufeh Nikfar,Mohammad Abdollahi
DOI: https://doi.org/10.1080/17425255.2024.2348488
2024-05-04
Expert Opinion on Drug Metabolism & Toxicology
Abstract:Introduction Irritable bowel syndrome (IBS), which presents a significant healthcare and socioeconomic burden, is one of the main issues in the field of therapy. Hence, it is imperative to tackle this matter by evaluating the safety and efficacy of the available treatments and determining the ideal approach for each patient.
pharmacology & pharmacy,biochemistry & molecular biology,toxicology
What problem does this paper attempt to address?